COMMUNIQUÉS West-GlobeNewswire

-
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
21/02/2024 -
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
21/02/2024 -
BioSyent Named to 2024 TSX Venture 50
21/02/2024 -
Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
21/02/2024 -
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
21/02/2024 -
Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET
21/02/2024 -
CervoMed to Participate in the BIO CEO and Investor Conference
21/02/2024 -
Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach
21/02/2024 -
Halo Dental Technologies to Showcase New Digital Dental Mirror at CDS Chicago Midwinter Meeting
21/02/2024 -
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
21/02/2024 -
Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19
21/02/2024 -
Sharps Technology Enters Latin American Market and Receives First Orders for Securegard Disposable Smart Safety Syringes from Strategic Distribution Partner in Colombia
21/02/2024 -
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance
21/02/2024 -
Theratechnologies présente ses résultats financiers pour le quatrième trimestre et l’exercice complet 2023 et des prévisions pour 2024
21/02/2024 -
Repligen Reports Fourth Quarter and Full Year 2023 Financial Results
21/02/2024 -
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
21/02/2024 -
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
21/02/2024 -
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
21/02/2024 -
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
21/02/2024
Pages